Oppenheimer comes to the defense of Questcor (QCOR -1.5%), which was crushed yesterday after...

|By:, SA News Editor

Oppenheimer comes to the defense of Questcor (QCOR -1.5%), which was crushed yesterday after arriving on TheStreetSweeper's crosshairs. In reiterating an Outperform, Oppenheimer says there is no evidence Questcor promotes its Acthar drug for off-label uses. However, the market continues to have its concerns; shares are selling off again today, giving back yesterday's AH gains in the process.